Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina”…
Month: April 2023
RingCentral Announces Date of First Quarter 2023 Financial Results Conference Call
BELMONT, Calif.–(BUSINESS WIRE)–$RNG #UCaaS—RingCentral, Inc. (NYSE: RNG), a leading provider of AI-powered global enterprise cloud…
Broadmark Realty Capital Declares Monthly Dividend for April 2023
SEATTLE–(BUSINESS WIRE)–Broadmark Realty Capital Inc. (NYSE: BRMK) (“Broadmark” or the “Company”), a specialty real estate…
Dine Brands Global, Inc. Completes Refinancing of its Class A-2-I Senior Secured Notes Through a Securitization
GLENDALE, Calif.–(BUSINESS WIRE)–Dine Brands Global, Inc. (NYSE: DIN) (“Dine Brands” or the “Corporation”), the parent…
Biocept Reports 2022 Financial Results
SAN DIEGO–(BUSINESS WIRE)–Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and…
Link Logistics and Carrier Collaborate to Drive Value Through Energy Efficiency
Carrier’s Abound solutions and EcoEnergy Insights enable Link Logistics to enhance the value of its…
Hope Bancorp Appoints Julianna Balicka Chief Financial Officer
LOS ANGELES–(BUSINESS WIRE)–Hope Bancorp, Inc. (NASDAQ: HOPE) (the “Company”), the holding company of Bank of…
Splunk Appoints Min Wang as Chief Technology Officer
Google, Visa and HP Veteran Joins Technology Leadership Team SAN FRANCISCO–(BUSINESS WIRE)–Splunk Inc. (NASDAQ: SPLK),…
At Home’s New Found & Fable Label Combines Global Influence with Collected Style
DALLAS–(BUSINESS WIRE)–At Home, The Home and Holiday Superstore, announced today the launch of its new…
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO…
Harvard Bioscience Schedules First Quarter 2023 Earnings Conference Call for April 25, 2023 at 9:00 AM ET
HOLLISTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce…
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in…
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) — via InvestorWire — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology…
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April…
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
America’s Leading Wireless Network Tops Competitors in New Industry Expert Report
In the latest report from Ookla®, T-Mobile’s network once again earned top rankings for fastest…
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected…
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE)…
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due…
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April…